483 related articles for article (PubMed ID: 32858471)
1. PROTACs: New method to degrade transcription regulating proteins.
Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
[TBL] [Abstract][Full Text] [Related]
2. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
3. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional Molecules beyond PROTACs.
Conway SJ
J Med Chem; 2020 Mar; 63(6):2802-2806. PubMed ID: 32157887
[TBL] [Abstract][Full Text] [Related]
7. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
[TBL] [Abstract][Full Text] [Related]
8. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
11. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
12. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
15. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
16. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
17. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
18. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
